Naveris Expands Coverage for NavDx Test
Naveris, Inc., a company at the forefront of precision oncology diagnostics focused on viral-induced cancers, recently announced an important advancement in healthcare accessibility. Blue Shield of California now provides coverage for Naveris' proprietary NavDx test, a pivotal development in the realm of diagnostics for Tumor Tissue Modified Viral (TTMV-HPV) DNA. This partnership is expected to significantly enhance patient access to cutting-edge diagnostic solutions.
The Importance of NavDx Testing
NavDx stands out as the first and only clinically validated blood test designed to detect circulating TTMV-HPV DNA. This innovative test offers a non-invasive technique to identify HPV-driven cancers long before they manifest through traditional clinical or radiological evidence. The clinical validity and utility of NavDx is backed by a wealth of research, with findings published in over 30 peer-reviewed scientific articles. Additionally, earlier this year, the Centers for Medicare & Medicaid Services (CMS) recognized NavDx as an Advanced Diagnostic Laboratory Test (ADLT).
Empowering Patients and Physicians
James McNally, the Chief Executive Officer of Naveris, expressed his enthusiasm for this collaboration, stating, “We are pleased to partner with Blue Shield of California to increase access to precision medicine diagnostics and to empower physicians and patients with valuable insights provided by TTMV-HPV DNA.” The NavDx test not only enhances surveillance capabilities but also enables the detection of disease recurrence at the molecular level. This is crucial for ensuring that patients receive timely and appropriate care suited to their unique circumstances.
Naveris' Mission and Achievements
The mission of Naveris, founded in 2017, is to improve health outcomes for individuals at risk of developing viral-induced cancers through pioneering molecular diagnostic technologies that facilitate earlier detection. With state-of-the-art laboratories located in Massachusetts and North Carolina, Naveris operates under rigorous accreditation from the College of American Pathologists and the New York State Department of Health. The facilities are also certified under Clinical Laboratory Improvement Amendments (CLIA) regulations, demonstrating a commitment to quality and reliability in testing.
Future Directions
Naveris is poised to increase the availability of NavDx testing nationwide, continuing its momentum in transforming patient care through precision oncology. The company not only aims to empower healthcare professionals with sophisticated diagnostic tools but also seeks to improve the journey for patients navigating cancer detection and treatment. The expansion of coverage by insurance providers like Blue Shield of California fosters a broader reach for these advancements, ensuring more patients can benefit from early diagnoses.
About Naveris
Naveris is dedicated to enhancing the quality of life for millions of people who are at risk of viral-induced cancers. Through relentless innovation in molecular diagnostics, Naveris allows for earlier intervention and improved management of these significant health threats. Its commitment to facilitating the best possible patient outcomes is evident in the validation and clinical impact of the NavDx test. For comprehensive information on Naveris and the clinical advantages of the NavDx test, please visit www.naveris.com and www.NavDx.com. It is important to note that the NavDx test has not yet received clearance or approval from the US Food and Drug Administration (FDA).
Frequently Asked Questions
What is the NavDx test?
The NavDx test is a proprietary blood test developed by Naveris to detect Tumor Tissue Modified Viral (TTMV-HPV) DNA, allowing for early identification of HPV-driven cancers.
Why is Blue Shield of California covering the NavDx test?
Blue Shield of California is expanding its coverage for the NavDx test to improve access to precision oncology diagnostics, facilitating better patient care and outcomes.
How does the NavDx test work?
The test uses a non-invasive method to detect circulating TTMV-HPV DNA in the blood, enabling early identification of potential cancers before they show clinical evidence.
What are the benefits of using the NavDx test?
The NavDx test aids in optimizing patient surveillance by identifying recurrence at the molecular level, ensuring timely intervention and appropriate care for patients.
Is Naveris a publicly traded company?
Naveris is a privately held company focused on precision oncology diagnostics and is not currently publicly traded.
